The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density

Kardiologia Polska

Volumn 69, Issue 6, 2011, Pages 573-578

  Celczyńska Bajew, Liliana ^a   Horst Sikorska, Wanda ^a   Bychowiec, Bartosz ^a   Wykrȩtowicz, Andrzej ^a   Wesoły, Joanna ^b   Michalak, Michał ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b ADAM MICKIEWICZ UNIVERSITY   (Poland)

Author keywords

Bone mineral density; Coronary artery disease; Osteoprotegerin; Polymorphism

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; OSTEOPROTEGERIN; THREONINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BONE DENSITY; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; QUESTIONNAIRE; RISK FACTOR;

EID: 79959290784     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Collin-Osdoby P. Regulation of vascular calcification by osteoblast regulatory factors RANKL and osteoprotegrin. Circulation Res, 2004; 95: 1046-1057. (Pubitemid 39557891)
2. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA, 2004; 4: 490-495. (Pubitemid 38988958)
3. Min H, Morony S, Sarosi I et al. Osteoprotegrin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Experim Med, 2000; 4: 463-474. (Pubitemid 30666247)
4. Pennisi P, Signorelli SS, Riccobene S et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int, 2004; 15: 389-395. (Pubitemid 38639334)
5. Sennerby U, Melhus H, Gedeborg R et al. Cardiovascular diseases and risk of hip fracture. JAMA, 2009; 302: 1666-1673.
6. Schoppet M, Priessner K, Hofbauer L. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscl Throm Vasc Biol, 2002; 22: 549-553.
7. Lorenc R, Kryśkiewicz E. Szlak RANKL/RANK/OPG i jego znaczenie w fizjologii i patofizjologii kości. Terapia, 2006; 3: 58-63.
8. Schoppet M, Henser S, Ruppert V et al. Osteoprotegerin expression in dendritic cell increases with maturation and is NF-kappa- dependent. J Cell Biochem, 2007; 100: 1430-1439. (Pubitemid 46515577)
9. Schoppet M, Sattler A, Schaefer J et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 2003; 88: 1024-1028. (Pubitemid 36337751)
10. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997; 89: 309-319. (Pubitemid 27199902)
11. Brandstrom H, Gerdhem P, Stiger F et al. Single nucleotide polymorphism In the human gene for osteoprotegerin are not related to bone mineral density or fracture in elderly women. Calcif Tissue Int, 2004; 74: 18-24. (Pubitemid 38166600)
12. Arko B, Prezejl J, Kocijancic A, Hudler P. Sequence variations In the osteoprotegerin gene promotor in patients with postmenopausal osteoporosis J Clin Endocrinol Metab, 2002; 87: 4080-4084.
13. Arko B, Prezejl J, Kocijancic A, Komel R. Association of the osteoprotegerin gene polymorphism with bone mineral density in postmenopausal women. Marturitas, 2005; 51: 270-279. (Pubitemid 40835947)
14. Choi J Y, Shin A, Park SK et al. Genetic polymorphism of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. Calcif Tissue Int, 2005; 77: 152-159.
15. Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphism In the osteoportegerin gene are associated with osteoporotic fractures. J Bone Miner Res, 2002; 17: 1245-1255. (Pubitemid 34680501)
16. Brandstrom H, Stiger F, Lind L. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegin is related to vascular morphology and function. Biochem Biophys Res Commun, 2002; 293: 13-17. (Pubitemid 34694163)
17. Hofbauer LC, Schoppet M. Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease. J Clin Endocrinol Metab, 2002; 87: 4078-4079.
18. Rhee EJ, Oh KW, Jung CH et al. The relationship between four single nucleotide polymorphism In the promotor region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. Clin Endocrinol (Oxf), 2006; 64: 689-697. (Pubitemid 43775009)
19. Soufi M, Schoppet M, Sattler A et al. Osteoprotegerin gene polimorphism in men with coronary artery disease. J Clin Endocrinol Metab, 2004; 89: 3764-3768. (Pubitemid 39071469)
20. Yamada Y,Ando F, Niino N, Shimokata H. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol Genet Metab, 2003; 80: 344-349. (Pubitemid 37324722)
21. Kim JG, Kim JH, Kim JU et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B(RANK) and RANK Ligand (RANKL) gene polymorphism and circulating OPG, soluble RANKL levels and bone mineral density in Korean postmenopausal women. Menopause, 2007; 14: 913-918. (Pubitemid 47517592)
22. Wynne F, Drummond F, o'Sullivan K et al. Investigation of the genetic influence of the OPG, VDR(Fok1), and COLIA1 Sp 1 polymorphism on BMD in the Irish population. Calcif Tissue Int, 2002; 71: 26-35.
23. Garcia-Unzueta MT, Rancho JA, Zarrabeitia MT et al. Association of the 163 A/G and 1181 G/C osteoprotegerin polymorphism with bone mineral density. Horm Metab Res, 2008; 40: 219-224. (Pubitemid 351690528)